Last reviewed · How we verify
Nurtec Odt (rimegepant)
Nurtec Odt (generic name: rimegepant) is a Calcitonin Gene-related Peptide Receptor Antagonist drug developed by Pfizer. It is currently FDA-approved (first approved 2020) for Migraine, Prevention of migraine attacks.
Rimegepant blocks the calcitonin gene-related peptide receptor.
Nurtec ODT is a medication used for the acute treatment of migraine with or without aura in adults and the prophylactic treatment of episodic migraine in adults. It works by blocking the calcitonin gene-related peptide type 1 receptor, a small molecule antagonist of this receptor.
At a glance
| Generic name | rimegepant |
|---|---|
| Sponsor | Pfizer |
| Drug class | Calcitonin Gene-related Peptide Receptor Antagonist |
| Target | calcitonin gene-related peptide receptor |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 2020 |
Mechanism of action
Rimegepant works by blocking the calcitonin gene-related peptide (CGRP) receptor, which is involved in pain signaling and vasodilation processes that contribute to migraine.
Approved indications
- Migraine
- Prevention of migraine attacks
Common side effects
- Nausea
- Abdominal pain/dyspepsia
- Hypersensitivity
- Dyspnea
- Severe rash
Key clinical trials
- A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea
- Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine (PHASE3)
- Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects (PHASE3)
- A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine (PHASE3)
- Randomized Study in Children and Adolescents With Migraine: Acute Treatment (PHASE3)
- Rimegepant Combined With AG Chemotherapy As First-Line Treatment For Metastatic Pancreatic Ductal Adenocarcinoma (PHASE1,PHASE2)
- A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine (PHASE3)
- Efficacy and Safety of Rimegepant for Acute Dizziness (PHASE2,PHASE3)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nurtec Odt CI brief — competitive landscape report
- Nurtec Odt updates RSS · CI watch RSS
- Pfizer portfolio CI
Frequently asked questions about Nurtec Odt
What is Nurtec Odt?
How does Nurtec Odt work?
What is Nurtec Odt used for?
Who makes Nurtec Odt?
What is the generic name of Nurtec Odt?
What drug class is Nurtec Odt in?
When was Nurtec Odt approved?
What development phase is Nurtec Odt in?
What are the side effects of Nurtec Odt?
What does Nurtec Odt target?
Related
- Drug class: All Calcitonin Gene-related Peptide Receptor Antagonist drugs
- Target: All drugs targeting calcitonin gene-related peptide receptor
- Manufacturer: Pfizer — full pipeline
- Therapeutic area: All drugs in Neuroscience
- Indication: Drugs for Migraine
- Indication: Drugs for Prevention of migraine attacks
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing